Objective: To assess whether impaired energy metabolism in skeletal muscle is a hallmark feature of patients with dominant optic atrophy due to several different mutations in the OPA1 gene.
D
OMINANT OPTIC ATROPHY (DOA), first described by Kjer, 1 is characterized by an insidious loss of central vision and color discrimination, in most cases with onset in the first decade of life, that variably progresses over the years. [1] [2] [3] The pathological findings in DOA are limited to a selective degeneration of retinal ganglion cells. 4 Most DOA cases are associated with mutations in the mitochondrial protein OPA1, a dynaminrelated guanine triphosphatase located in the inner mitochondrial membrane and essential for mitochondrial fusion. 5, 6 Most mutations affecting the OPA1 gene (GenBank NC_000003.11) in patients with DOA are predicted to induce haploinsufficiency, being frameshift, stop codon, splicing errors, or deletions/insertions, all leading to a variably truncated form of OPA1. moplegia, mitochondrial myopathy with cytochrome-c oxidase-negative ragged red fibers, and accumulation of mitochondrial DNA (mtDNA) multiple deletions. [8] [9] [10] [11] [12] The OPA1 protein is composed of 960 amino acids and has 8 isoforms, variably expressed in tissues. The leading function of OPA1 is to promote and regulate mitochondrial fusion in association with mitofusins 1 and 2.
3, 13 The latter are also dynamin-related guanine triphosphatases located on the external mitochondrial membrane. Defective fusion, as variably seen with OPA1 mutations or by suppressing OPA1 expression with RNA interference, leads to loss of tubular-reticular organization of the mitochondrial network in cells and a net increase of fragmented mitochondria. 14, 15 Besides its role in mitochondrial fusion, OPA1 is also involved in shaping mitochondrial cristae, 15 in particular participating in the compartmentalization of cytochrome c and thus regulating cytochrome c availability to initiate apoptosis. 16 In fact, suppressing OPA1 expression by RNA interference led to profound alteration of cristae morphology, loss of membrane potential, cytochrome c release, and apoptotic death of cells. 15 We first documented the impairment of oxidative phosphorylation (OXPHOS) in skeletal muscle from patients with DOA carrying the common c.2708delTTAG microdeletion studied by phosphorus 31 magnetic resonance spectroscopy ( 31 P-MRS). 17 Recently, defective adenosine triphosphate (ATP) synthesis, mainly driven by complex I substrates, was also documented in fibroblasts of patients carrying different haploinsufficiency OPA1 mutations.
14 Loss of mitochondrial membrane potential and coupling defects have been shown in cells carrying OPA1 mutations associated with DOA or DOAplus syndromes. 18, 19 However, some contradictory results have been reported by other studies failing to show defective OXPHOS in patients with DOA. 20, 21 The aim of this study was to investigate the effect of a wide range of OPA1 mutations on muscle OXPHOS, expanding previous 31 P-MRS examinations of patients carrying the c.2708delTTAG microdeletion. We recruited a total of 18 patients with DOA carrying different haploinsufficiency or missense OPA1 mutations, 5 of whom also had available skeletal muscle biopsy for histological and mtDNA investigations. [17] years; age range, 21-75 years). This series of patients also includes the 6 previously described by Lodi et al 17 (families 1 and 2, cases 1-6). All patients gave written consent to their inclusion in this study, which was approved by the local ethical committee.
METHODS

SUBJECTS
Fifteen subjects were clinically affected with DOA as documented by a comprehensive ophthalmologic examination including best-corrected visual acuity measurement, slitlamp biomicroscopy, intraocular pressure measurement, indirect ophthalmoscopy, optic nerve head photography, and visual field testing by Humphrey Field Analyzer (Zeiss-Humphrey Systems, Dublin, California). These patients showed a variably pale optic disc with reductions of visual acuity and central vision defect, with relative sparing of peripheral vision (Table 1) . Three cases were classified as subclinical given that none of them had a visual deficit, even though a slight temporal pallor was recognized at examination of fundus oculi in 2 cases. None of the 18 subjects carrying the OPA1 mutations were limited in daily activities because of their poor vision; in particular, none of them had to lead a sedentary lifestyle. Furthermore, neither patients nor healthy control subjects followed any specific physical training regimen.
Extraocular abnormalities were observed at neurological examination, including hypoacusia (2 patients), brisk deep tendon reflexes (6 patients), and mild ataxia (2 patients). Adjunctive features included migraine (2 subjects), febrile seizures (2 subjects), and muscle cramps (2 subjects). The only 2 patients carrying a missense mutation, 1 previously described by AmatiBonneau et al 8 (proband in family 2), were brothers and had some further extraocular features including ptosis (Table 1) and white matter hyperintense lesions on T2-weighted magnetic resonance images (Table 1) .
Five cases underwent muscle biopsy, and in 10 of 18 patients we also evaluated serum lactate levels after standardized muscle exercise as previously reported. 22 Venous blood samples were collected prior to exercise (2 samples taken 5 minutes apart), immediately after completion of exercise, and 15 minutes after completion of exercise. The muscle exercise was carried out for 15 minutes on a cycloergometer standardized by the heart rate.
22
MUSCLE BIOPSIES
Quadriceps or tibialis anterior muscle biopsies were performed by open surgery under local anesthesia. Muscle specimens were frozen in cooled isopentane and stored in liquid nitrogen for histological and histoenzymatic analysis including Gomori modified trichrome staining, cytochrome-c oxidase activity, succinate dehydrogenase activity, and double cytochrome-c oxidase/succinate dehydrogenase staining according to standard protocols.
GENETIC STUDIES
The OPA1 gene was amplified by polymerase chain reaction (PCR) with specific primers designed to amplify all exons and flanking intronic regions and sequenced as previously described. 23 Total RNA was isolated from whole blood using the PAXgene Blood RNA system (Qiagen, Hilden, Germany). Singlestranded complementary DNA was synthesized with the SuperScript First-Strand Synthesis System (Invitrogen, Carlsbad, California), and overlapping fragments of the OPA1 complementary DNA were amplified by PCR prior to direct DNA sequencing as described previously. 24 Long-range PCR on mtDNA was performed to screen for presence of mtDNA deletions as previously detailed. 8 The PCR was performed using Takara Ex Taq DNA polymerase (Takara Shuzo Corp, Kyoto, Japan). The PCR products were separated by a 0.8% agarose gel.
SKELETAL MUSCLE 31 P-MRS
Investigations by 31 P-MRS were performed in a 1.5-T scanner on the right calf muscle as described. 17 Spectra were acquired with a repetition time of 5 seconds, at rest (128-scan spectrum), during an aerobic incremental exercise (12-scan spectra), and the following recovery (32 two-scan spectra). The
WWW.ARCHNEUROL.COM 68 muscle was exercised by plantar flexion at 0.66 Hz against a pedal using a pneumatic ergometer. The force resistance of the pedal was 10% of lean body mass. After the acquisition of 2 spectra, corresponding to the first 2 minutes of exercise, the resistance was increased by 5% of lean body mass for each subsequent 1-minute spectral acquisition. As soon as the last 12-scan exercise spectrum was collected, the exercise was stopped and data were collected for 5 minutes 20 seconds. Spectra were processed by the time-domain fitting routine AMARES/MRUI, and the concentrations of inorganic phosphate, phosphocreatine, and adenosine diphosphate (ADP) as well as pH were assessed as reported. 25 The phosphorylation potential was calculated 25 
STATISTICAL ANALYSIS
Dataarepresentedasmeans(SDs).Statisticalanalysiswasperformed by t test for unpaired data, and PϽ.05 was taken to be significant.
RESULTS
All patients included in this study carried a pathogenic mutation in the OPA1 gene. In 16 patients from 7 unrelated families, the OPA1 mutation was predicted to lead to haploinsufficiency, whereas a further family (family 8, cases 17 and 18) carried a missense mutation. The c.2708-2711delTTAG common microdeletion was present in 6 subjects (families 1 and 2), 17 the c.1516ϩ1GϾC splicing error was present in 1 subject (family 3), the c.948 ϩ 3AϾT splicing error was present in 3 subjects (family 4), the c.2819-2AϾC splicing error was present in 2 subjects (family 5), the c.1346_1347insC frameshift mutation was present in 2 subjects (family 6), and the c.2815delC frameshift mutation was present in 2 subjects (family 7). The last 2 subjects from family 8 carried the missense mutation c.2729TϾA (Val910Asp). 8 All pedigrees are shown in the eFigure.
The clinical and laboratory findings of the subjects included in this study are summarized in Table 1 . Serum lactate levels after standardized muscle exercise were abnormally elevated in 4 of the 10 available subjects. Muscle biopsies of 5 patients did not show clear-cut hallmarks of mitochondrial myopathy, such as cytochrome-c oxidase-negative or ragged red fibers, and were considered within the limits of normal muscle morphology. However, both patients from family 8, carrying the missense mutation, had nonspecific signs of myopathy (Table 1 and Figure 1) .
Molecular evaluation of mtDNA by long-range PCR showed a low abundance of mtDNA deletions in 4 of 5 muscle biopsies, compatible with their age-related accumulation (age range, 35-58). However, using specific PCR primers for the common deletion as well as for the 7.7-and 8.1-kilobase deletions, we were able to detect variable amounts of these deletions (data not shown) in all biopsies, including the younger subject (aged 35 years) who failed to show multiple mtDNA deletions with longrange PCR. Table 1 ) (original magnification ϫ20). In both cases, nonspecific signs of myopathy (nuclear centralization, fibrosis, and muscle fiber variability) were observed. Dyshomogeneous distribution of the respiratory enzymes occasionally affected the center of some fibers, and a parcellar increase of subsarcolemmal staining can be noted with cytochrome-c oxidase/succinate dehydrogenase staining (B and D). E, An agarose electrophoresis separation of the wild-type mitochondrial DNA (mtDNA) long-range polymerase chain reaction-amplified fragment of 11 845 base pairs (bp) (see "Methods" for details ); lane 7, a patient with chronic progressive external ophthalmoplegia who was previously diagnosed as having mtDNA multiple deletions; and lane 8, a negative control. The molecular weight (MW) is shown by marker X (Roche, Basel, Switzerland), and the sizes of some reference bands are indicated (in base pairs). Long-range polymerase chain reaction showed low abundance of mtDNA multiple deletions in all muscle biopsies from patients with dominant optic atrophy except patient 16 from family 7. Study by 31 P-MRS showed reduced phosphorylation potential in the calf muscle of the patients with OPA1 mutations who were at rest, indicating reduced energy reserve (Table 1 ). However, only 4 patients with OPA1 mutations showed resting phosphorylation potential below the normal range (Figure 2 and Figure 3) . Compared with healthy control subjects, patients with OPA1 mutations reached the same degree of phosphocreatine consumption and pH at the end of the exercise but with shorter exercise duration (Table 2) , indicating reduced oxidative capacity. All postexercise measures of mitochondrial ATP synthesis rate (time constant of postexercise phosphocreatine resynthesis reported as a function of the minimum cytosolic pH reached during recovery normalized to pH 7.00, 17 V, and V max ) were abnormal in the patients with OPA1 mutations (Table 2 and Figure 2 ). In particular, skeletal muscle V max was reduced by 36% in the group of patients with OPA1 mutations compared with healthy control subjects, with only 2 patients having values within the normal range (Figure 2 and Figure 3) .
Variable reductions in resting phosphorylation potential ( Figure 3 ) and V max ( Figure 3) were present in skeletal muscle in association with each pathogenic OPA1 mutation. The reduction from the normal mean of the phosphorylation potential at rest ranged from 4% in the two c. 2729TϾA (Val910Asp) carriers to 45% in the c.1516ϩ1GϾC carrier. More importantly, the reduction of V max for mitochondrial ATP production ranged from 28% in patients carrying the c.1346_1347insC mutation to 49% in c.948ϩ3AϾT carriers. The only 2 patients carrying the c.2729TϾA (Val910Asp) missense mutation showed a reduction in skeletal muscle V max that was no more severe than that found in association with the other OPA1 mutations leading to haploinsufficiency (Figure 3 ).
COMMENT
In this study, we showed that different OPA1 mutations are associated with a clear deficit of skeletal muscle OXPHOS as assessed in vivo using 31 P-MRS. This finding extends our initial observation of patients with DOA carrying the c.2708-2711delTTAG 4-base deletion in exon 27, 17 included also in this study, demonstrating that mutations in the OPA1 gene result in a reduced rate of mitochondrial ATP synthesis in skeletal muscle. Although none of the 5 patients who underwent muscle biopsy displayed the hallmarks of mitochondrial myopathy, 4 of 10 patients tested for serum lactate levels after exercise showed abnormally high lactate levels. Despite the fact that the methods used for muscle mtDNA analysis were not quantitative, the multiple deletions detected did not seem sufficient to justify the OXPHOS deficiency demonstrated by 31 P-MRS. Furthermore, quantitative evaluation of mtDNA copy number in these muscle biopsies did not reveal significant variations compared with control subjects (Luisa Iommarini, PhD, unpublished data, December 2009). Investigation by 31 P-MRS revealed defective oxidative metabolism not only during and after effort but also at rest. Reduced phosphorylation potential at rest is a common finding not only in patients with mitochondrial myopathies 26 but also in those with OXPHOS deficits without myopathy, for example, patients with Leber hereditary optic neuropathy (LHON) who have mutations affecting complex I subunits 27, 28 where histopathological evidence of mitochondrial myopathy is generally absent or mild. [29] [30] [31] The relationship between resting and exercise deficit of muscle oxidative metabolism is unclear. However, it should be pointed out that, despite the significant reduction in phosphorylation potential at rest in patients with OPA1 mutations and DOA as a group, 14 of 18 patients (78%) showed phosphorylation potential values within the normal range ( Figure 2 and Figure 3 ) while postexercise V max was below the normal range in all but 2 patients (Figure 2 and Figure 3) .
The relatively small number of patients studied for each OPA1 mutation did not allow for a tight correlation of genotype with OXPHOS impairment. However, 31 P-MRS showed that V max for mitochondrial ATP production was clearly reduced in association with each of the OPA1 mutations investigated and that both missense and haploinsufficiency mutations were associated with impaired muscle OXPHOS. It is debated whether all mutations in the OPA1 gene may impair OXPHOS 21 or whether only certain mutations are able to affect it 20 and ultimately whether the OXPHOS defect is relevant to the pathogenesis of optic neuropathy. 32 In this study, we also tested the hypothesis that the OPA1 mutations inducing haploinsufficiency may induce abnormal accumulation of mtDNA deletions similar to some missense mutations, which were previously associated with a DOA-plus phenotype. [8] [9] [10] [11] [12] Our results do not support the hypothesis in this series of patients. The traces of mtDNA deletions found in our patients are possibly compatible with the aging process. TheremaybeseveralpathogenicmechanismsofOXPHOS deficit secondary to OPA1 mutations in the absence of pathogenicamountsofmtDNAmultipledeletions.Themain function of OPA1 is to regulate mitochondrial fusion. Defective fusion, as variably seen with OPA1 mutations, leads to a loss of tubular-reticular organization of the mitochondrial network in cells, an abnormal shape of mitochondrial cristae, and a net increase of fragmented mitochondria. 14, 15 In 9 of the 18 patients described here, carrying OPA1 mutations inducing haploinsufficiency (5 patients with c.2708-2711delTTAG, 1 patient with c.1516ϩ1GϾC, 2 patients with c.2819-2AϾC, and 1 patient with c.1346_1347insC), Zanna et al 14 documented defective ATP synthesis driven by complex I substrates in fibroblasts.
The remodeling of the cristae morphology due to defective fusion is a possible mechanism, which could account for the OXPHOS defect. In particular, the supercomplex organization of the respiratory chain may be affected, leading to decreased ATP synthesis even though the single complexes can still carry out their specific activities in the presence of appropriate substrates. The complex I-driven defect of ATP synthesis is possibly more directly related to the early involvement of the optic nerve, which cannot be associated with mtDNA instability as recently highlighted by studies of a DOA animal model with mutant OPA1 32 where the search for mtDNA deletions in the retinal ganglion cells was negative. It remains the formal, still untested possibility that other mtDNA defects (point mutations) may accumulate besides multiple deletions, and an appropriate investigation to resolve this point is needed.
The 2 brothers from family 8, 1 of whom was included in our previous study on patients with DOA plus (proband in family 2 from the study by Amati-Bonneau et al 8 ), stood out from the group in various respects. They were the only patients showing some nonspecific signs of myopathy at muscle biopsy, and both showed white matter abnormalities on brain magnetic resonance imaging. This family was found to carry a missense mutation (Val910Asp) that did not affect the guanine triphosphatase domain as in all of the other patients with DOA-plus phenotype described by Amati-Bonneau et al. 8 Thus, this family was probably improperly aggregated to the other DOA-plus cases but showed rather a more severe phenotype than canonical nonsyndromic DOA, likely belonging to the wider range of intermediate phenotypes that has been recently described in the largest series of patients with DOA plus so far. 12 It must be noted that in the case series of patients described here who visited us with only visual loss, adjunctive extraocular features were observed at neurological examination or by cerebral magnetic resonance imaging as in the case of patient 10 from family 4. Thus, this study confirms a wide variability in clinical expression of OPA1 mutations, including those leading to haploinsufficiency, possibly qualifying many patients as having DOA plus.
The current results have striking similarities with our previous findings in patients with LHON, for whom the OXPHOS defect is due to mtDNA mutations affecting complex I. 4, 33, 34 In fact, 31 P-MRS investigation of skeletal muscle from subjects carrying one of the common LHON pathogenic mutations at positions 11778/ND4, 3460/ ND1, or 14484/ND6 showed, as in the patients with OPA1-related DOA, a reduced phosphorylation potential at rest and a reduced rate of skeletal muscle mitochondrial ATP production after effort. 27, 28, 35 The few reports of muscle biopsy in patients with LHON have shown mild subsarcolemmal mitochondrial proliferation, as documented by the succinate dehydrogenase stain and at electron microscopy, sometimes with aberrant mitochondria carrying paracrystalline inclusions. [29] [30] [31] The similarities between LHON and DOA converge to a final pathway of biochemical dysfunction involving complex I, as we and others have recently documented, 14, 19 and the common selective involvement of retinal ganglion cells. 4, 33, 34 In conclusion, our current results demonstrate that various different OPA1 mutations, either missense or leading to haploinsufficiency, share an OXPHOS impairment in skeletal muscle as shown by 31 P-MRS and serum lactate levels. Furthermore, this may result in a more widespread clinical expression, qualifying some of these patients as having DOA plus as recently emphasized. 
